Aimsco Limited

The unique biological therapy administered under the brand AIMSPRO® is owned by Aimsco Limited.

AIMSPRO® was fully developed, initially produced and tested with the assistance of a major US university in 1999. Aimsco Limited owns all of the intellectual property rights for this innovative treatment and it is the registered proprietor of a suite of patents Worldwide. In addition, Aimsco is the owner of numerous trade marks for AIMSPRO® registered in many countries internationally.

Developing innovative treatment

The treatment – whose disease-arresting capability has been confirmed in a number of pre-clinical studies, both in vitro and in vivo – has been found to alleviate the effects of such diseases as Multiple Sclerosis, Krabbe’s Leucodistrophy, Amyotrophic Lateral Sclerosis, and Alzheimer’s Disease. The promising results of tests, which included a 21-patient study of those confirmed with ALS and a long-term study of more than 150 patients diagnosed with MS, confirmed the drug’s tolerability and safety.

In addition, a recent multi-patient case study for those with Alzheimer’s Disease showed stabilisation and even reversal of the disease. A case study using AIMSPRO® to treat chronic wounds, meanwhile, showed an accelerated healing process when compared to standard practice, highlighting the versatility and diverse capabilities of the treatment.

Compliance and regulatory approval

Aimsco Limited’s life-changing AIMSPRO® treatment – a biological product derived from a caprine hyper-immune serum source – was granted a manufacturer’s specials licence by the MHRA in the United Kingdom in 2005, followed in 2007 by approval by the TGA of Australia for use under categories A and B of the Specials Access Scheme. As such, doctors have been given authority to prescribe the medication on a compassionate use basis.

AIMSPRO® has also been granted Orphan Drug designation by the US FDA for the treatment of Amyotrophic Lateral Sclerosis (2009) and Systemic Sclerosis (2013), while the TGA granted AIMSPRO Orphan Drug status for the treatment of Krabbe’s Disease (2005) and for Amyotrophic Lateral Sclerosis (2009).

Intellectual property

AIMSPRO® has a strong, established patent position with ten patent families and 84 patents granted and additional applications pending. The intellectual property includes the manufacturing process, composition of matter and defined mechanism of action. Patent families include inflammatory disorders and conditions, and autoimmune diseases.

With an international reputation and freedom to operate in jurisdictions including major European countries, USA, Canada, New Zealand and Australia, Aimsco Limited will be delivering AIMSPRO® in conjunction with others which will help enrich the lives of those suffering from a series of debilitating illnesses.